Brainstorm Cell Therapeutics Reports Q1 2025 Financial Results with Reduced Net Loss

Brainstorm Cell Therapeutics Inc. reported its financial results for the first quarter of 2025, revealing a net loss of $2.86 million, a decrease from the $3.40 million loss recorded in the same period last year. The loss per share improved to $0.45 from $0.75, reflecting a higher weighted average number of shares outstanding, which increased to 6.34 million from 4.32 million. The company’s total assets rose significantly to $3.57 million as of March 31, 2025, compared to $1.83 million at the end of 2024, primarily due to increased cash and cash equivalents, which reached $1.64 million, up from $187,000.

Research and development expenses for the quarter were $1.30 million, up from $961,000 in the prior year, attributed to higher payroll and stock-based compensation costs. General and administrative expenses also increased to $1.79 million from $1.51 million, driven by a rise in stock-based compensation and consulting fees. The company’s financial income rose to $46,000 from $13,000, contributing to the overall reduction in net loss.

In terms of strategic developments, Brainstorm is actively pursuing regulatory approval for its NurOwn® treatment for amyotrophic lateral sclerosis (ALS). The company has engaged with the FDA regarding a Special Protocol Assessment for a planned Phase 3b trial, which aims to address previous concerns raised during the review of its Biologics License Application (BLA). The BLA was withdrawn in November 2023, but the company remains committed to advancing its clinical programs and has recently submitted an Investigational New Drug amendment for NurOwn®.

Operationally, Brainstorm has made significant strides in its manufacturing capabilities, leasing a GMP-certified facility in Tel Aviv to enhance production capacity for NurOwn®. The company currently employs 29 individuals across its U.S. and Israeli operations, focusing on developing its proprietary cell therapy platform. Additionally, Brainstorm has been involved in various funding activities, including an at-the-market offering that generated approximately $706,000 in gross proceeds during the quarter.

Looking ahead, Brainstorm anticipates the need for additional capital to support its ongoing clinical trials and commercialization efforts. The company is exploring various financing options, including public and private sales of its common stock and warrants. However, management has expressed uncertainty regarding its ability to secure necessary funding on favorable terms, which could impact its operations and ability to continue as a going concern.